Tasly Delivers Profit Growth on Flat Revenue, Bolstering China Resources Pharmaceutical

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

An update from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.

China Resources Pharmaceutical Group has disclosed key unaudited interim figures from its subsidiary Tasly Pharmaceutical for the six months to 30 June 2026, highlighting the performance of one of its core assets in the mainland market. Tasly, listed in Shanghai, remains 28% owned indirectly by China Resources Pharmaceutical and is fully consolidated, underscoring its strategic importance to the group’s overall earnings profile.

During the reporting period, Tasly’s total operating revenue slipped 2.03% year on year to RMB 4.20 billion, but profitability improved markedly across key metrics. Operating profit rose 14.87% to RMB 1.05 billion, while net profit attributable to shareholders climbed 15.23% to RMB 892.68 million, aided by a 36.01% surge in net profit excluding extraordinary items.

Basic earnings per share increased from RMB 0.52 to RMB 0.60 and weighted average return on net assets edged up to 6.98%, indicating more efficient capital use despite flat top-line momentum. The company’s total assets were broadly stable at RMB 15.30 billion, and equity attributable to shareholders expanded 5.42%, lifting net assets per share to RMB 8.75 and reinforcing balance sheet strength.

These interim numbers, though unaudited and subject to confirmation in Tasly’s forthcoming 2026 interim report, suggest that China Resources Pharmaceutical’s consolidated results will benefit from improved margins at the subsidiary level. For investors, the combination of modest revenue pressure and stronger profitability may signal a shift toward higher-value products or tighter cost management, potentially enhancing the group’s competitive position in China’s pharmaceutical sector.